GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Modalis Therapeutics Corp (TSE:4883) » Definitions » EV-to-Revenue

Modalis Therapeutics (TSE:4883) EV-to-Revenue : (As of Jun. 02, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Modalis Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Modalis Therapeutics's enterprise value is 円1,308.43 Mil. Modalis Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was 円0.00 Mil. Therefore, Modalis Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Modalis Therapeutics's EV-to-Revenue or its related term are showing as below:

During the past 6 years, the highest EV-to-Revenue of Modalis Therapeutics was 11067.16. The lowest was -26.75. And the median was 168.58.

TSE:4883's EV-to-Revenue is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.28
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-02), Modalis Therapeutics's stock price is 円69.00. Modalis Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was 円0.00. Therefore, Modalis Therapeutics's PS Ratio for today is .


Modalis Therapeutics EV-to-Revenue Historical Data

The historical data trend for Modalis Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modalis Therapeutics EV-to-Revenue Chart

Modalis Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial - 168.58 11,655.29 170.45 -

Modalis Therapeutics Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Modalis Therapeutics's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Modalis Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Modalis Therapeutics's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Modalis Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Modalis Therapeutics's EV-to-Revenue falls into.



Modalis Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Modalis Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1308.428/0
=

Modalis Therapeutics's current Enterprise Value is 円1,308.43 Mil.
Modalis Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Modalis Therapeutics  (TSE:4883) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Modalis Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=69.00/0
=

Modalis Therapeutics's share price for today is 円69.00.
Modalis Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Modalis Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Modalis Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Modalis Therapeutics (TSE:4883) Business Description

Traded in Other Exchanges
N/A
Address
16-5 Nihombashi-Kabuto-cho, Chuo-ku, Tokyo, JPN, 103-0026
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.

Modalis Therapeutics (TSE:4883) Headlines

No Headlines